The HealthCare Institute of New Jersey (HINJ) is a trade association that since 1997 has served as the voice for our state’s leading research-based biopharmaceutical and medical technology companies.
HINJ strives to raise awareness and appreciation of the clinical and economic value of expanding patient access to medical innovations that improve outcomes and quality of life, and works to sustain the life sciences as New Jersey’s premier industry and a pillar of the state’s economy.
New Jersey proudly champions its life sciences industry and is globally recognized as the “Medicine Chest of the World” for its world-renowned cluster of life sciences companies.
For over 135 years, New Jersey has been a global leader in medical science. It offers a dynamic innovation ecosystem for researching and developing new medicines, therapies, diagnostics and technologies that improve the quality of patients’ lives. This includes over 3,200 life sciences companies and the largest concentration of scientists and engineers per square mile in the U.S.
Governor Mikie Sherrill keynotes HINJ’s 2026 annual ‘State of the Industry’ event, lauding New Jersey’s life sciences and our state’s innovation ecosystem for saving lives around the world while driving New Jersey’s workforce and economy.
We diligently monitor a number of policy debates — both in Washington, DC and Trenton.
By Chrissy Buteas, President and CEO, HealthCare Institute of New Jersey (HINJ – www.hinj.org) and Dan Leonard, Executive Director, We Work For Health (WWFH – www.weworkforhealth.org) Published on April 29, 2006
Trenton, April 6, 2026 ― Last week, HINJ released a statement addressing proposed federal tariffs on pharmaceuticals and key materials. The statement was referenced in several New Jersey media outlets
Trenton, April 2, 2026 ― Chrissy Buteas, President and Chief Executive Officer of the HealthCare Institute of New Jersey (HINJ – www.hinj.org), released the following statement regarding today’s announcement on
